Urologic Cancer clinical trials at University of California Health

1 research study open to eligible people

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
open to eligible people ages 18 years and up
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
at UCLA UCSD

Last updated: September 13, 2023